Key insights
- Lucid Diagnostics reported Q1 earnings matching estimates but revenue falling short. The stock is down significantly over the last 3 and 12 months. InvestingPro assesses the company's financial health as weak. While the EPS revisions were positive, the revenue miss and weak financial health suggest a slightly negative, but not substantial, impact on the broader US equity market.
Investing.com - Lucid Diagnostics (NASDAQ: LUCD) reported first quarter EPS of $-0.0700, in line with the analyst estimate of $-0.0700. Revenue for the quarter came in at $1.26M versus the consensus estimate of $1.38M.
Lucid Diagnostics’s stock price closed at $1.02. It is down -23.3100% in the last 3 months and down -17.0700% in the last 12 months.
Lucid Diagnostics saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Lucid Diagnostics’s stock price’s past reactions to earnings here.
According to InvestingPro, Lucid Diagnostics’s Financial Health score is "weak performance".
Check out Lucid Diagnostics’s recent earnings performance, and Lucid Diagnostics’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar